

Remarks

Claims 95-132 and 138-167 are pending in the subject application. By this Supplemental Election, Applicants have provided the proper status identifier of each claim as required by the Notice of Non-Compliant Amendment.

In addition, the Notice of Non-Compliant Amendment indicates that this reply must include the identification of a specific insulin sensitizer agent and a specific FBPase inhibitor. Applicants respectfully assert that this information was provided on the first page of the Election dated October 17, 2006 as Compound H and troglitazone (a thiazolidinedione), without traverse.

Applicants' undersigned representative certifies that no new material is added by this submission. Favorable consideration of the pending claims is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,

/FRANKCEISENSCHENK/

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl